Suicide Preventive Psychosocial Treatment for Youths
Launched by KAROLINSKA INSTITUTET · Apr 16, 2025
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new program called SAFETY, which aims to help young people who have recently attempted suicide. The main goal is to see if this program is better at preventing further suicide attempts compared to the usual treatment that they currently receive. Researchers believe that SAFETY could not only reduce the chances of a young person attempting suicide again but also be effective for a long time after the treatment ends. Additionally, they want to find out if this program is cost-effective, meaning it could save money while providing important help to those in need.
To participate in this trial, young people aged 10 to 17 who have attempted suicide in the last three months and have at least one parent or caregiver willing to join will be eligible. Unfortunately, those who have severe symptoms that would make it hard to participate or who do not understand Swedish well enough will not be able to take part. If eligible, participants will receive either the SAFETY intervention or the usual treatment, and they will be monitored to see how well each approach works. This trial is an important step towards finding effective support for teenagers in crisis.
Gender
ALL
Eligibility criteria
- Inclusions criteria:
- • 1. Suicide attempt in the last 3 months
- • 2. Age 10-17 years
- • 3. At least one primary caregiver (multiple is allowed) willing to participate in treatment
- Exclusion criteria:
- • 1. Symptoms obstructing participation in assessments or treatment
- • 2. Insufficient understanding of the Swedish language in youth and/or caregiver
- • 3. Enrolled in Dialectical Behavioral Therapy
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsingborg, , Sweden
Karlstad, , Sweden
Kungsbacka, , Sweden
Stockholm, , Sweden
Uppsala, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported